@FierceMedDev: Boston Scientific posts positive Watchman data. Item | Follow @FierceMedDev
@MarkHFierce: Fledgling Dx company GeneCentric is raising money to support a lung cancer Dx commercial launch. More | Follow @MarkHFierce
@DamianFierce: More worry for Intuitive Surgical as the FDA gets involved in the scrutiny of da Vinci robots. Story | Follow @DamianFierce
> One of the study sites for Medtronic's ($MDT) CoreValve pivotal trial has received an FDA warning letter, but Medtronic says the problems cited don't affect the data gathered on the device. Article
> Imaging device company OmniVision ($OVTI) pulled in revenue of $423.5 million last quarter, an increase of about 128% over the previous, and the company more than doubled its net income to $21.3 million. Results
> Zimmer ($ZMH) says federal investigators have closed their probe of the company's Asian operation. Story
> ArthroCare ($ARTC) picked up FDA clearance for the SpeedLock HIP Knotless Fixation implant, designed to help surgeons reattach soft tissue to bone in hip procedures. News
> Touch Medical Solutions, a division of DMH International ($DMHI), won FDA approval for its medical imaging software suite, TouchPACS, considered a Class II device by the agency. Item
> Wisconsin startup Swallow Solutions has raised just over $1 million in Series A financing to commercialize its novel dysphagia treatment platform, designed to treat patients with difficulty swallowing. More
Biotech News
@FierceBiotech: From FierceBiotechIT.com : GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner | Follow @FierceBiotech
@JohnCFierce: Lundbeck gets EU nod for new drug to fight alcohol addiction--$300M tops; no U.S. plans. Story | Follow @JohnCFierce
@RyanMFierce: Alere grabbed some Gates Foundation funding for Tuberculosis and HIV testing products. Release | Follow @RyanMFierce
> As sequestration dawns, FDA supporters scramble to ease woes on drug reviews. Report
> Facebook, Google geeks 'hack' into cancer research problem with mobile game. More
> FDA pins approval on once-monthly version of blockbuster Abilify. Article
Pharma News
@FiercePharma: Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article | Follow @FiercePharma
@EricPFierce: Must be some folks sorry Mylan got Agila and they didin't. Hikma says it is getting interest in its injectables biz. Story | Follow @EricPFierce
> Roche dropping Herceptin price in India by 30%. Report
> Lundbeck, Otsuka's new Abilify Maintena to face entrenched rivals. More
> Fewer generics approved in 2012 but still a banner year. Story